Brief: Aligos Therapeutics reports fourth-quarter and full-year 2024 results
10/03/2025 14:48
March 10 (Reuters) - ALIGOS THERAPEUTICS Q4 EPS USD -13.08 ALIGOS THERAPEUTICS Q4 OPERATING EXPENSES USD 21.192 MILLION ALIGOS THERAPEUTICS Q4 NET INCOME USD -82.15 MILLION ALIGOS THERAPEUTICS Q4 INCOME FROM OPERATIONS USD -20.563 MILLION ALIGOS THERAPEUTICS Q4 PRETAX PROFIT USD -82.123 MILLION Source text: nGNX6CT8Rv Further company coverage: ALGS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue